We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

30 hedge funds and large institutions have $3.45M invested in Traws Pharma in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

3% more funds holding

Funds holding: 29 → 30 (+1)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

41% less capital invested

Capital invested by funds: $5.87M → $3.45M (-$2.42M)

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$548K
2
VF
Virtu Financial
New York
+$291K
3
HF
HRT Financial
New York
+$252K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$248K
5
Squarepoint
Squarepoint
New York
+$211K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$672K
2
SAMH
Shanda Asset Management Holdings
British Virgin Islands
-$109K
3
Barclays
Barclays
United Kingdom
-$65.3K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$59K
5
FIA
FNY Investment Advisers
New York
-$56K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.94M +$548K +2,218 +14%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$252K +$248K +1,004 +71%
BlackRock
3
BlackRock
New York
$245K – – –
VF
4
Virtu Financial
New York
$124K +$291K +1,179 New
HF
5
HRT Financial
New York
$111K +$252K +1,019 +2,215%
PCM
6
Perkins Capital Management
Minnesota
$105K +$247K +1,000 New
BPA
7
Beacon Pointe Advisors
California
$95K +$67.7K +274 +43%
Squarepoint
8
Squarepoint
New York
$93K +$211K +855 +3,054%
Citadel Advisors
9
Citadel Advisors
Florida
$81K +$190K +768 New
QP
10
Quilter Plc
United Kingdom
$80K +$82.3K +333 +78%
Northern Trust
11
Northern Trust
Illinois
$78K +$56.9K +230 +44%
HWA
12
Hillcrest Wealth Advisors
New Jersey
$70K – – –
Jane Street
13
Jane Street
New York
$32K +$42.5K +172 +129%
UBS Group
14
UBS Group
Switzerland
$24K -$25.5K -103 -31%
JCM
15
Jacobi Capital Management
Pennsylvania
$22K +$52.6K +213 New
JP Morgan Chase
16
JP Morgan Chase
New York
$17K +$41K +166 New
BCM
17
Bayesian Capital Management
New York
$16K +$37.8K +153 New
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$15K +$15.3K +62 +81%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$11K +$25.5K +103 New
RJA
20
Raymond James & Associates
Florida
$11K +$25.5K +103 New
Victory Capital Management
21
Victory Capital Management
Texas
$8K – – –
ECM
22
ETrade Capital Management
Virginia
$6K +$14.6K +59 New
Two Sigma Advisers
23
Two Sigma Advisers
New York
$5K +$12.9K +52 New
9WM
24
9258 Wealth Management
Ohio
$4K – – –
Rockefeller Capital Management
25
Rockefeller Capital Management
New York
$3K -$5.44K -22 -42%
1
2

TRAW Hedge Fund Activity: Q3 2020 in Review

30 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2020, worth a combined $3.45M — down 41% from $5.87M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TRAW positions and 9 closed out — a net gain of 1 holder — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $548K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $672K sold.

  • 30 institutional investors held Traws Pharma (TRAW) as of Q3 2020, up from 29 in Q2 2020.
  • Funds reported $3.45M of Traws Pharma stock for Q3 2020, down 41% quarter-over-quarter.
  • 10 funds opened new Traws Pharma positions in Q3 2020 and 9 closed out, a net change of +1 holder.
  • The largest Traws Pharma buyer in Q3 2020 was Vanguard Group, an estimated $548K added.
  • The largest Traws Pharma seller in Q3 2020 was Renaissance Technologies, an estimated $672K sold.

Based on aggregated 13F filings for Q3 2020.